Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Efalizumab: continuous therapy for chronic psoriasis.

Jennifer Clay Cather1, Alan Menter

  • 1Baylor University Medical Center, 5310 Harvest Hill Rd., Ste. 260, Dallas, TX75230, USA.

Expert Opinion on Biological Therapy
|April 19, 2005
PubMed
Summary

Efalizumab effectively treats moderate-to-severe plaque psoriasis, with about 30% of patients achieving significant skin clearance within 12 weeks. This humanized monoclonal antibody offers a safe, long-term option for managing psoriasis symptoms.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Efficacy of long-term risankizumab treatment for moderate-to-severe plaque psoriasis: Subgroup analyses by baseline characteristics and psoriatic disease manifestations through 256 weeks (LIMMitless trial).

Journal of the European Academy of Dermatology and Venereology : JEADV·2024
Same author

Summary of Research: Switching Between Adalimumab Reference Product and BI 695501 in Patients with Chronic Plaque Psoriasis (VOLTAIRE-X): A Randomized Controlled Trial.

Dermatology and therapy·2023
Same author

Response to letter to the editor "It's time to consider a new topical algorithm for psoriasis".

Journal of the American Academy of Dermatology·2023
Same author

Switching Between Adalimumab Reference Product and BI 695501 in Patients with Chronic Plaque Psoriasis (VOLTAIRE-X): A Randomized Controlled Trial.

American journal of clinical dermatology·2022
Same author

Narrative Review of the Emerging Therapeutic Role of Brodalumab in Difficult-to-Treat Psoriasis.

Dermatology and therapy·2022
Same author

Cryptococcal meningitis associated with interleukin-17 inhibitor use for psoriasis.

Dermatologic therapy·2022

Area of Science:

  • Immunology
  • Dermatology
  • Pharmacology

Background:

  • Psoriasis is a chronic inflammatory skin condition affecting millions globally.
  • Current treatments for moderate-to-severe plaque psoriasis often have limitations in efficacy or safety.
  • Efalizumab targets CD11a, a key molecule in T-cell activation and migration to the skin.

Purpose of the Study:

  • To evaluate the efficacy and safety of efalizumab for moderate-to-severe plaque psoriasis.
  • To assess the long-term maintenance therapy benefits of efalizumab.
  • To determine the proportion of patients achieving significant clinical response.

Main Methods:

  • Utilized controlled clinical trials to assess efalizumab's impact on psoriasis.
  • Administered efalizumab via weekly subcutaneous self-injections.

Related Experiment Videos

  • Monitored patient response using Psoriasis Area and Severity Index (PASI) scores, specifically targeting PASI-75 response.

    • Main Results:

    • Approximately 30% of patients achieved a PASI-75 response within 12 weeks.
    • Continued maintenance therapy demonstrated further clinical benefit up to 36 months.
    • Efalizumab showed a favorable safety and tolerability profile in controlled trials.

    Conclusions:

    • Efalizumab is an effective treatment option for moderate-to-severe plaque psoriasis.
    • The drug offers a safe and tolerable choice for long-term disease management.
    • Weekly subcutaneous injections of efalizumab improve patient quality of life.